135 related articles for article (PubMed ID: 38479445)
21. Differential effect of cancer-associated fibroblast-derived extracellular vesicles on cisplatin resistance in oral squamous cell carcinoma
Kang SH; Oh SY; Lee KY; Lee HJ; Kim MS; Kwon TG; Kim JW; Lee ST; Choi SY; Hong SH
Theranostics; 2024; 14(2):460-479. PubMed ID: 38169528
[No Abstract] [Full Text] [Related]
22. STAT3- and GSK3β-mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma.
Maji S; Shriwas O; Samal SK; Priyadarshini M; Rath R; Panda S; Das Majumdar SK; Muduly DK; Dash R
Carcinogenesis; 2019 Mar; 40(1):173-183. PubMed ID: 30395230
[TBL] [Abstract][Full Text] [Related]
23. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
[TBL] [Abstract][Full Text] [Related]
24. Reversal of cisplatin resistance in oral squamous cell carcinoma by piperlongumine loaded smart nanoparticles through inhibition of Hippo-YAP signaling pathway.
Sa P; Singh P; Panda S; Swain RK; Dash R; Sahoo SK
Transl Res; 2024 Jun; 268():63-78. PubMed ID: 38499286
[TBL] [Abstract][Full Text] [Related]
25. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
26. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m
Shriwas O; Priyadarshini M; Samal SK; Rath R; Panda S; Das Majumdar SK; Muduly DK; Botlagunta M; Dash R
Apoptosis; 2020 Apr; 25(3-4):233-246. PubMed ID: 31974865
[TBL] [Abstract][Full Text] [Related]
27. GAS5 alleviates cisplatin drug resistance in oral squamous cell carcinoma by sponging miR-196a.
Yuan X; Jing Y; Guang M; Zhu J; Wang J; Wang Y; Zhang Y
J Int Med Res; 2022 Oct; 50(10):3000605221132456. PubMed ID: 36310502
[TBL] [Abstract][Full Text] [Related]
28. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer.
Alam M; Mishra R
Life Sci; 2021 Sep; 280():119705. PubMed ID: 34111459
[TBL] [Abstract][Full Text] [Related]
29. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
[TBL] [Abstract][Full Text] [Related]
30. METTL3/14 and IL-17 signaling contribute to CEBPA-DT enhanced oral cancer cisplatin resistance.
Qiao X; Zhu L; Song R; Shang C; Guo Y
Oral Dis; 2023 Apr; 29(3):942-956. PubMed ID: 34807506
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA‑198 suppresses tumour growth and metastasis in oral squamous cell carcinoma by targeting CDK4.
Kang Y; Zhang Y; Sun Y
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 33982769
[TBL] [Abstract][Full Text] [Related]
32. Direct Binding of Cisplatin to p22phox, an Endoplasmic Reticulum (ER) Membrane Protein, Contributes to Cisplatin Resistance in Oral Squamous Cell Carcinoma (OSCC) Cells.
Hung CC; Li FA; Liang SS; Wang LF; Lin IL; Chiu CC; Lee CH; Chen JY
Molecules; 2020 Aug; 25(17):. PubMed ID: 32825798
[TBL] [Abstract][Full Text] [Related]
33. WNT3 promotes chemoresistance to 5-Fluorouracil in oral squamous cell carcinoma via activating the canonical β-catenin pathway.
Zhang X; Sun K; Gan R; Yan Y; Zhang C; Zheng D; Lu Y
BMC Cancer; 2024 May; 24(1):564. PubMed ID: 38711026
[TBL] [Abstract][Full Text] [Related]
34. Tigecycline exerts an antitumoral effect in oral squamous cell carcinoma.
Ren A; Qiu Y; Cui H; Fu G
Oral Dis; 2015 Jul; 21(5):558-64. PubMed ID: 25581076
[TBL] [Abstract][Full Text] [Related]
35. The human HECA interacts with cyclins and CDKs to antagonize Wnt-mediated proliferation and chemoresistance of head and neck cancer cells.
Dowejko A; Bauer R; Bauer K; Müller-Richter UD; Reichert TE
Exp Cell Res; 2012 Mar; 318(5):489-99. PubMed ID: 22100912
[TBL] [Abstract][Full Text] [Related]
36. New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects.
Hu H; Li B; Wang J; Tan Y; Xu M; Xu W; Lu H
Biomed Pharmacother; 2023 Jul; 163():114778. PubMed ID: 37137185
[TBL] [Abstract][Full Text] [Related]
37. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
[TBL] [Abstract][Full Text] [Related]
38. Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma.
Yang M; Luo Q; Chen X; Chen F
J Nanobiotechnology; 2021 Aug; 19(1):259. PubMed ID: 34454534
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.
Sudo S; Kajiya H; Okano S; Sasaki M; Katsumata Y; Ohno J; Ikebe T; Hiraki A; Okabe K
Cancer Sci; 2020 Apr; 111(4):1113-1123. PubMed ID: 32012401
[TBL] [Abstract][Full Text] [Related]
40. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis.
Zhou X; Ren Y; Liu A; Jin R; Jiang Q; Huang Y; Kong L; Wang X; Zhang L
Sci Rep; 2014 Dec; 4():7461. PubMed ID: 25514838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
